v3.25.1
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS Unaudited - USD ($)
$ in Millions
3 Months Ended
Mar. 31, 2025
Mar. 31, 2024
Adjustments to reconcile net (loss) income to cash provided by operating activities:    
Share-based awards compensation expense $ (8.2) $ (6.4)
Non-cash rent expense (2.8) (4.4)
Financing activities    
Payments on finance leases (3.8) (3.7)
CNK    
Operating activities    
Net (loss) income (38.6) 25.3
Adjustments to reconcile net (loss) income to cash provided by operating activities:    
Depreciation 49.4 48.9
Amortization of intangible and other assets 0.1 0.5
Amortization of original issue discount and debt issuance costs 2.1 2.4
Amortization of accumulated losses (gains) for amended swap agreements 0.9 (3.1)
Share-based awards compensation expense 8.2 6.4
(Gain) loss on disposal of assets and other (4.1) 0.4
Non-cash rent expense (2.8) (4.4)
Equity in income of affiliates (0.9) (3.8)
Deferred income tax benefit (29.4) (37.1)
Distributions from equity investees 4.8 1.3
Changes in assets and liabilities and other (109.5) (52.5)
Net cash used for operating activities (119.1) (22.7)
Investing activities    
Additions to theatre properties and equipment (22.1) (23.5)
Proceeds from sale of theatre properties and equipment and other 6.8 0.2
Net cash used for investing activities (15.3) (23.3)
Financing activities    
Dividends paid to stockholders (9.9) 0.0
Repurchases of common stock under share repurchase program (200.0) 0.0
Repayments of long-term debt (1.6) (1.9)
Restricted stock withholdings for payroll taxes (17.1) (4.2)
Payments on finance leases (3.8) (3.7)
Other financing activities 2.3 (0.6)
Net cash used for financing activities (230.1) (10.4)
Effect of exchange rate changes on cash and cash equivalents 6.6 (4.1)
Decrease in cash and cash equivalents (357.9) (60.5)
Cash and cash equivalents:    
Beginning of period 1,057.3 849.1
End of period 699.4 788.6
CUSA    
Operating activities    
Net (loss) income (34.3) 27.9
Adjustments to reconcile net (loss) income to cash provided by operating activities:    
Depreciation 49.4 48.9
Amortization of intangible and other assets 0.1 0.5
Amortization of original issue discount and debt issuance costs 1.3 1.6
Amortization of accumulated losses (gains) for amended swap agreements 0.9 (3.1)
Share-based awards compensation expense 7.9 6.0
(Gain) loss on disposal of assets and other (4.1) 0.4
Non-cash rent expense (2.8) (4.4)
Equity in income of affiliates (0.9) (3.8)
Deferred income tax benefit (29.3) (34.3)
Distributions from equity investees 4.8 1.3
Changes in assets and liabilities and other (104.8) (50.4)
Net cash used for operating activities (111.1) (16.4)
Investing activities    
Additions to theatre properties and equipment (22.1) (23.5)
Proceeds from sale of theatre properties and equipment and other 6.8 0.2
Net cash used for investing activities (15.3) (23.3)
Financing activities    
Repayments of long-term debt (1.6) (1.9)
Restricted stock withholdings for payroll taxes (17.1) (4.2)
Payments on finance leases (3.8) (3.7)
Other financing activities 2.1 (0.6)
Net cash used for financing activities (20.4) (10.4)
Effect of exchange rate changes on cash and cash equivalents 6.6 (4.1)
Decrease in cash and cash equivalents (140.2) (54.2)
Cash and cash equivalents:    
Beginning of period 827.4 612.4
End of period 687.2 558.2
NCM | CNK    
Adjustments to reconcile net (loss) income to cash provided by operating activities:    
Interest accrued related to significant financing component 5.4 5.5
Amortization of NCM screen advertising advances (8.2) (8.1)
NCM | CUSA    
Adjustments to reconcile net (loss) income to cash provided by operating activities:    
Interest accrued related to significant financing component 5.4 5.5
Amortization of NCM screen advertising advances (8.2) (8.1)
NCMI | CNK    
Adjustments to reconcile net (loss) income to cash provided by operating activities:    
Net losses (gains) on investment in NCMI 3.5 (4.4)
NCMI | CUSA    
Adjustments to reconcile net (loss) income to cash provided by operating activities:    
Net losses (gains) on investment in NCMI $ 3.5 $ (4.4)

Source